Anti-Human/Mouse Integrin β7 – Purified in vivo PLATINUM™ Functional Grade
Anti-Human/Mouse Integrin β7 – Purified in vivo PLATINUM™ Functional Grade
Product No.: B763
Clone FIB504 Target Integrin Beta 7 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names β7 Integrin, integrin βp, ITGB7 Isotype Rat IgG2a κ Applications B , CyTOF® , FC , in vivo , IP |
Antibody DetailsProduct DetailsReactive Species Human ⋅ Mouse Host Species Rat Recommended Isotype Controls Recommended Isotype Controls Recommended Dilution Buffer Immunogen TK1 cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893536 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this FIB504 antibody for staining cells in flow cytometry is ≤0.5 µg per 106 cells in a volume of 100 μl or 100 μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? B This antibody has been reported to block beta7 integrin mediated cell adhesion for In vitro and In vivo studies. IP CyTOF® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone FIB504 recognizes an epitope on human/mouse integrin β7.
Background Integrin β7 antibody, clone FIB504, recognizes integrin β7, a 130 kDa membrane glycoprotein of the Ig superfamily. Integrin β7 forms heterodimers with both the α4 (CD49d) and aE (CD103) integrins. α4β7 integrin is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors1,2. It mediates adhesion to mucosal endothelial cells, promoting leukocyte transendothelial migration through interactions with mucosal addressin cell adhesion molecule-1 (MAdCAM-1)3,4. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells5,6, subsets of dendritic cells7, and regulatory T cells (Tregs)8. It facilitates retention in the gut epithelial layer via interactions with E-cadherin9. Anti-β7 antibodies block both the homing to and retention in the gut of pathogenic T cells10 and are currently under evaluation in a phase 3 clinical trial to treat inflammatory bowel disease11. Antigen Distribution Integrin α4β7 is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells, subsets of dendritic cells, and regulatory T cells (Tregs)8. Ligand/Receptor CD49d/β7: VCAM-1 (CD106), MAdCAM-1 and fibronectin; CD103/β7: E-cadherin Function Lymphocyte adhesion, hematopoietic progenitor cells migration NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology . Neuroscience Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone FIB504 is commonly used in vivo in mice for functional blocking studies of integrin β7, particularly to inhibit integrin β7-mediated cell adhesion and immune cell migration. The main in vivo applications include:
Additional details:
Summary of main in vivo applications in mice:
Less commonly, FIB504 may also be used in flow cytometry of cells isolated from treated animals to confirm receptor occupancy or modulation in vivo. Apart from FIB504, which targets integrin β7, several other antibodies and proteins are frequently used together with FIB504 in immunological and virological studies, especially in the context of integrin-mediated cell adhesion and HIV research. Commonly used antibodies or proteins with FIB504:
Context and Applications:
Summary table:
These panels enable comprehensive analysis of immune cell subsets, trafficking, and infection mechanisms where integrin β7 and its partners play essential roles. Clone FIB504, an antibody targeting integrin β7, has yielded several significant findings across multiple research areas, demonstrating its versatility as both a research tool and potential therapeutic target. Role in Multiple Myeloma Cell Adhesion and MigrationResearch has demonstrated that blocking integrin β7 with FIB504 significantly reduces multiple myeloma (MM) cell adhesion to stromal elements including bone marrow stromal cells (BMSCs), fibronectin (FN), and E-cadherin (E-CDH). The antibody also impaired MM cell migration, with these effects being validated through complementary shRNA silencing studies. Rescue experiments using a silent mutant ITGB7 that resisted shRNA knockdown successfully restored both adhesive and migratory functions, confirming the specificity of integrin β7's role in these cellular processes. Development as a Humanized Therapeutic AntibodyFIB504 served as the parent antibody for developing rhuMAb Beta7, a humanized monoclonal IgG1κ antibody targeting integrin β7. The humanization process involved CDR grafting into a consensus framework, which initially resulted in complete loss of antigen binding. Researchers restored binding through framework optimization, identifying a critical L78F substitution in VH, followed by CDR repair mutations (T31D and Y32L in CDR-L1) that fully restored β7 binding affinity comparable to the parent antibody. This demonstrates the technical challenges and solutions in translating research antibodies into potential therapeutics. Differential Effects in Experimental Autoimmune EncephalomyelitisComparative studies in mouse models of experimental autoimmune encephalomyelitis (EAE) revealed important mechanistic distinctions between integrin-targeting strategies. While anti-α4 antibodies (mPS/2) significantly ameliorated disease severity with statistical improvements in both disease scores (P = 0.003) and histological inflammation scores (P = 0.009), the anti-β7 antibody (muFIB504) showed no effect on disease severity or CNS inflammatory cellular infiltration. Strikingly, survival rates differed dramatically: 90% of animals receiving anti-α4 treatment survived to day 21, compared to only 30% with anti-β7 (muFIB504) treatment and 36% in controls (P = 0.0005). These findings suggest that while α4β7 integrin plays a role in mucosal immunity, the α4β1 integrin pathway may be more critical for CNS inflammation in EAE. Functional Characteristics and ApplicationsFIB504 recognizes a 130 kDa glycoprotein epitope on both human and mouse integrin β7, demonstrating cross-species reactivity that enhances its utility in translational research. The antibody effectively blocks β7 integrin-mediated cell adhesion in both in vitro and in vivo studies. Integrin β7 functions by forming heterodimers with α4 (CD49d) to create the α4β7 integrin complex or with αE (CD103) to form αEβ7 integrin. The α4β7 complex mediates adhesion to mucosal endothelial cells through interactions with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), promoting leukocyte transendothelial migration—a critical process in inflammatory responses. These collective findings establish FIB504 as a valuable tool for investigating integrin β7 biology across diverse disease contexts, from cancer cell behavior to autoimmune inflammation, while highlighting the context-dependent nature of integrin-targeted interventions. Dosing regimens of clone FIB504 (anti-integrin β7 antibody) in mouse models vary by disease model, experimental aim, and administration schedule. In published studies, the most detailed and consistent dosing regimens are reported in models of autoimmunity, such as lupus or colitis, but less frequently in other indications. Key Dosing Regimens Across Models:
Summary Table: FIB504 Dosing by Mouse Model
Essential Context and Supporting Details:
Additional Relevant Information:
No example was found of alternate regimens for non-systemic autoimmune models or tumor models using FIB504; where precision is necessary, consult the methods section of relevant studies or directly titrate in pilot experiments. In summary: The most common FIB504 in vivo regimen is 500 µg i.p. every 2 days (e.g., days 7, 9, and 11) in models like MRL-lpr, but regimens can be adjusted depending on model requirements and experimental goals. References & Citations1. Andrew DP, et al. (1996) Eur J Immunol. 26(4):897-905 2. Murakami JL, et al. (2016) Stem Cells Dev. 25(1):18-26 3. Hu MC, et al. (1992) Proc Natl Acad Sci USA. 89(17):8254-8 4. Hamann A, et al. (1994) J Immunol. 152(7):3282-93 5. Hadley GA Higgins JM. (2014) Adv Exp Med Biol. 819:97–110 6. Farstad IN., et al. (1996) Immunology. 89:227–37 7. Jaensson E., et al. (2008) J Exp Med. 205:2139–49 8. Allez M, et al. (2002) Gastroenterology. 123(5):1516-26 9. Schön MP, et al. (1999) J Immunol. 162(11):6641-9 10. Stefanich EG, et al. (2011) Br J Pharmacol. 162(8):1855-1870 11. Smids C, et al. (2017) J Crohns Colitis. 11(4):500-508 Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-1177 | |
C247 | |
F1175 | |
R1214 | |
S571 |
Formats Available
Prod No. | Description |
---|---|
I-1106 | |
I-1143 | |
I-1141 | |
I-1150 | |
I-1142 | |
I-1144 | |
I-1145 | |
B763 |
